- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Study from NCPA sheds new light on med synchronization programs
LAKE FOREST, Ill. — The Food and Drug Administration has approved a generic chemotherapy drug made by Hospira, the drug maker said.
Hospira announced the approval of gemcitabine injection in the 200-mg, 1-g and 2-g formulations and plans to launch the drug in September. The drug is a generic version of Eli Lilly's Gemzar.
Various versions of the drug had sales of $750 million in 2010, according to Hospira.